<b>Background:</b> Sodium/glucose cotransporter-2 inhibitors (SGLT2is), such as dapagliflozin and empagliflozin, are currently a standard therapy for heart failure (HF) patients. This evidence concerns the gene SLC5A2 and heart failure.